[Analysis of surface markers of expanded human umbilical cord blood cells in vitro].
OBJECTIVE
To explore the optimal timing for in vitro expansion and transplantation of umbilical cord blood hematopoietic cells.


METHODS
Hematopoietic cells from human umbilical cord blood were cultured with G-CSF, GM-CSF, rIL-3, rIL-6, SCF and Epo in a long term culture system, the cell cycle and cellular markers were analysed dynamically.


RESULTS
CD(3)(+), CD(4)(+)/CD(45RO)(+) and CD(8)(+)/CD(45RO)(+) cells increased at day 3, and reached the highest level at day 7, decreased at day 14, and remained lower level at day 21. CD(4)(+) and CD(8)(+) cells showed no change at day 7, decreased at day 14, and decreased further at day 21. CD(4)(+)/CD(45RA)(+) and CD(8)(+)/CD(45RA)(+) cells decreased after day 3, and decreased further at day 14. HLA-DR(+) cells increased from day 3 to day 7. CD(34)(+) cells increased at day , reached the highest level at day 7, and decreased at day 14. CD(34)(+), CD(34)(+) CD(38)(-), CD(34)(+) CD(38)(+) cells increased 8.8, 7.4 and 8.7 fold at day 7, respectively, as compared with that precultured. The cells in the S phase increased at day 21.


CONCLUSIONS
This culture system is able to expand hematopoietic cells of human umbilical cord blood and keeps them intact. The number of hematopoietic cells reached the highest level in the culture from day 7 to day 14, which is the optimal time for transplantation.
Qiu
L
L
Central Laboratory, Zhejiang Provincial pepole's Hospital, Hangzhou 310014, China.
Zhou
Y
Y
Xia
X
X
Huang
P
P
Lin
M
M
D015703:Antigens, CD / Q000032:analysis*; D017252:CD3 Complex / Q000032:analysis; D015704:CD4 Antigens / Q000032:analysis; D016827:CD8 Antigens / Q000032:analysis; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects / Q000276:immunology; D002478:Cells, Cultured; D004921:Erythropoietin / Q000494:pharmacology; D005312:Fetal Blood / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D006684:HLA-DR Antigens / Q000032:analysis; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007377:Interleukin-3 / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D017493:Leukocyte Common Antigens / Q000032:analysis; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D019089:Stem Cell Factor / Q000494:pharmacology; D013997:Time Factors
D015703:Antigens, CD; D017252:CD3 Complex; D015704:CD4 Antigens; D016827:CD8 Antigens; D006684:HLA-DR Antigens; D007377:Interleukin-3; D015850:Interleukin-6; D019089:Stem Cell Factor; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D017493:Leukocyte Common Antigens